+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania

Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania

Journal of Infectious Diseases 204(2): 268-273

The World Health Organization recommends mass treatment as part of a trachoma control strategy. However, scant empirical data from hyperendemic communities exist on the number of rounds of treatment needed to reach a goal of <5% prevalence in children. We determined the prevalence of trachoma and infection with Chlamydia trachomatis in communities after 3-7 years of annual mass treatment in Tanzania. Seventy-one communities with trachoma and annual azithromycin coverage data were enrolled. A cross-sectional survey of ≥100 randomly selected children aged <5 years in each community was performed. Children were examined for clinical trachoma, and swab samples were taken for determination of ocular C. trachomatis infection. After 3 years of mass treatment, the prevalence of trachoma decreased in a linear fashion with number of years of mass treatment, whereas decreased prevalences of C. trachomatis infection were related to the extent of the previous year's azithromycin coverage. Our model suggests that, for communities with baseline trachoma prevalence of 50% and annual treatment coverage of 75%, >7 years of annual mass treatment will be needed to reach a prevalence of trachoma of <5%. Country programs in trachoma-endemic regions must realistically expect that several years of annual mass treatment may be necessary to eliminate trachoma.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054685224

Download citation: RISBibTeXText

PMID: 21673038

DOI: 10.1093/infdis/jir257

Related references

Trachoma and ocular Chlamydia trachomatis rates in children in trachoma-endemic communities enrolled for at least three years in the Tanzania National Trachoma Control Programme. Tanzania Journal of Health Research 11(3): 103-110, 2009

Antibiotic Resistance in Young Children in Kilosa District, Tanzania 4 Years after Mass Distribution of Azithromycin for Trachoma Control. American Journal of Tropical Medicine and Hygiene 97(3): 815-818, 2017

Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. American Journal of Tropical Medicine and Hygiene 85(4): 691-696, 2011

The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa. Parasites and Vectors 10(1): 624, 2017

Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases 54(2): 253-256, 2012

Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization 79(7): 632-640, 2001

Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clinical Infectious Diseases 56(11): 1519-1526, 2013

Household willingness to pay for azithromycin treatment for trachoma control in the United Republic of Tanzania. Bulletin of the World Health Organization 81(2): 101-107, 2003

Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. Bmc Public Health 14: 1176, 2014

Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia. Ophthalmic Epidemiology 18(1): 20-29, 2011

Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 379(9811): 143-151, 2012

Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology 102(5): 680-686, 2018

Mass treatment with azithromycin for trachoma control: participation clusters in households. Plos Neglected Tropical Diseases 4(10):, 2010

Acceptability of azithromycin for the control of trachoma in Northern Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene 99(9): 656-663, 2005

Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds. Plos Neglected Tropical Diseases 6(3): E1576, 2012